T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

AI nuclear energy background, future innovation of disruptive technology

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Previous article

Buprenorphine prescription remained constant during the first year of COVID-19 pandemic

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News